BioCentury | Sep 1, 2018
Politics, Policy & Law

Back to School: A pathway to Biopharma 3.0

As market and social forces continue to tighten around the biopharmaceutical industry, drug companies need to start evolving toward a new business model that both capitalizes on the potential of new technologies and accommodates society’s...
BC Week In Review | Jan 26, 2018
Company News

BIA intervenes on plausibility in patent law in Supreme Court case

The U.K. Bioindustry Association said the U.K. Supreme Court granted it permission to intervene in the court's review of Warner-Lambert Company LLC v. Generics UK Ltd and Actavis to examine the issue of plausibility in...
BioCentury | May 12, 2014
Strategy

Build up to break up

Pfizer Inc. continues to give signals that the grand plan is to break itself up, and the reality looks like it absolutely needs AstraZeneca plc 's assets to make it work. Pfizer already has internally...
BC Innovations | Nov 10, 2011
Targets & Mechanisms

Countering chemo-induced metastasis

Two independent research teams have elucidated mechanisms by which cisplatin and paclitaxel can promote lung metastases in mice, providing links between the chemotherapies and the known metastatic effects of upregulating VEGF receptor 1 and matrix...
BioCentury | Apr 18, 2011
Strategy

Supercharging Astex

SuperGen Inc. and Astex Therapeutics Ltd. are betting that by combining the former's cash with the latter's pipeline and drug discovery platform, they can create a mid-tier cancer company. SuperGen has plenty of cash from...
BioCentury | Jan 31, 2011
Strategy

Lysing what it sees

Since the approval of Dendreon Corp. 's Provenge finally validated the idea of cancer immunotherapy, one of the next big questions has been how this treatment modality would be incorporated into the portfolios of major...
BC Innovations | Sep 2, 2010
Targets & Mechanisms

GSK's topoisomerase in the hole

Fluoroquinolone antibiotics work by blocking bacterial topoisomerase IIA, but bacterial resistance to this class of drugs is rising faster than new treatments can be developed. 1-3 Researchers at GlaxoSmithKline plc now have generated a new...
BioCentury | Mar 8, 2010
Strategy

OSI Chronicles

OSI Chronicles Shares of OSI Pharmaceuticals Inc. jumped 139% to an all-time high of $91.10 in April 2004 when Tarceva erlotinib met the primary endpoint in a Phase III trial in non-small cell lung cancer...
BioCentury | Feb 1, 2010
Regulation

Begging questions about REMS

FDA's draft guidance on the content of REMS submissions raises almost as many questions as it answers, including how drug makers are supposed to monitor third parties - over which they have no authority - without violating...
BioCentury | Nov 10, 2008
Regulation

Narrowing down preemption

The oral arguments at the U.S. Supreme Court in Wyeth v. Levine last week suggest that the first decision in favor of FDA preemption of state tort laws in a prescription drug case is a...
Items per page:
1 - 10 of 367
BioCentury | Sep 1, 2018
Politics, Policy & Law

Back to School: A pathway to Biopharma 3.0

As market and social forces continue to tighten around the biopharmaceutical industry, drug companies need to start evolving toward a new business model that both capitalizes on the potential of new technologies and accommodates society’s...
BC Week In Review | Jan 26, 2018
Company News

BIA intervenes on plausibility in patent law in Supreme Court case

The U.K. Bioindustry Association said the U.K. Supreme Court granted it permission to intervene in the court's review of Warner-Lambert Company LLC v. Generics UK Ltd and Actavis to examine the issue of plausibility in...
BioCentury | May 12, 2014
Strategy

Build up to break up

Pfizer Inc. continues to give signals that the grand plan is to break itself up, and the reality looks like it absolutely needs AstraZeneca plc 's assets to make it work. Pfizer already has internally...
BC Innovations | Nov 10, 2011
Targets & Mechanisms

Countering chemo-induced metastasis

Two independent research teams have elucidated mechanisms by which cisplatin and paclitaxel can promote lung metastases in mice, providing links between the chemotherapies and the known metastatic effects of upregulating VEGF receptor 1 and matrix...
BioCentury | Apr 18, 2011
Strategy

Supercharging Astex

SuperGen Inc. and Astex Therapeutics Ltd. are betting that by combining the former's cash with the latter's pipeline and drug discovery platform, they can create a mid-tier cancer company. SuperGen has plenty of cash from...
BioCentury | Jan 31, 2011
Strategy

Lysing what it sees

Since the approval of Dendreon Corp. 's Provenge finally validated the idea of cancer immunotherapy, one of the next big questions has been how this treatment modality would be incorporated into the portfolios of major...
BC Innovations | Sep 2, 2010
Targets & Mechanisms

GSK's topoisomerase in the hole

Fluoroquinolone antibiotics work by blocking bacterial topoisomerase IIA, but bacterial resistance to this class of drugs is rising faster than new treatments can be developed. 1-3 Researchers at GlaxoSmithKline plc now have generated a new...
BioCentury | Mar 8, 2010
Strategy

OSI Chronicles

OSI Chronicles Shares of OSI Pharmaceuticals Inc. jumped 139% to an all-time high of $91.10 in April 2004 when Tarceva erlotinib met the primary endpoint in a Phase III trial in non-small cell lung cancer...
BioCentury | Feb 1, 2010
Regulation

Begging questions about REMS

FDA's draft guidance on the content of REMS submissions raises almost as many questions as it answers, including how drug makers are supposed to monitor third parties - over which they have no authority - without violating...
BioCentury | Nov 10, 2008
Regulation

Narrowing down preemption

The oral arguments at the U.S. Supreme Court in Wyeth v. Levine last week suggest that the first decision in favor of FDA preemption of state tort laws in a prescription drug case is a...
Items per page:
1 - 10 of 367